), n=15) were not different to control results. Eight patients had carcinomas (rectal (2), sigmoid (4), and caecal (2)) all of which were adenocarcinomas. The cancers (193.6 (40.2), n=8) synthesised more PGE2 than control specimens (p<0001), but were not different to polyps. Cancerassociated mucosa (140.3 (27.7) n=8) synthesised more PGE2 than control and polypassociated mucosa. Colorectal neoplasia is associated with a progressive increase in PGE2 synthesis which may have a role in tumourigenesis and be a pathophysiological explanation for the beneficial effects of NSAIDs in animal models and human disease.
Human and animal work in colorectal carcinogenesis has suggested an association with increased prostaglandin (PG) synthesis. Transformation from premalignant to a malignant state may be related to increased PG synthesis in susceptible individuals. Prostanoids, in particular PGE2 are produced in increased amounts by human colonic tumour cells.'I2 Prostaglandins may play a role in tumour development and progression; they modulate tumour cell growth and facilitate tumour cell progression.3 4 Animal models of colorectal cancer have shown increased prostaglandin production from carcinoma cells.5 In addition, it has been shown that non-cancerous or background mucosa in tumour bearing animals produces increased amounts of PGE2. It has been suggested that the development of large bowel tumours may be related to the level of prostaglandin synthesis. 6 The ability of certain NSAIDs to suppress colonic tumourigenesis in animal models of colorectal cancer implies that PGs are involved. 79 We have, therefore, investigated the changes in colonic mucosal PGE2 synthesis in the human adenoma-carcinoma sequence. as specimens from the polyps synthesised 178-0 (55 0) (n=27) pg PGE2/mg tissue. Polyps synthesised more PGE2 than the background mucosa (p<0-001) and the mucosa of control patients (p<0001). The ability of tissues from the polyp-associated background mucosa to synthesise PGE2, however, was not different to that of controls. Biopsy specimens from the background mucosa of patients with carcinoma synthesised (mean (SD)) 140-3 (27-7) (n=8) pg PGE2/mg tissue, and specimens from the carcinomas synthesised 193-6 (40 2) (n=8) pg PGE2/mg tissue. The carcinoma-associated background mucosa synthesised more PGE2 than control mucosa (p<0001) and polyp-associated background mucosa (p<005). The carcinomas synthesised more PGE2 than their background mucosa (p<0-01). There was no difference in the abilities of polyps and carcinomas to synthesise PGE2. Figure 2 shows known that PGs are involved in proliferation and metastasis.3 " It is also known that PGE2 has an effect on the immune system, and may reduce immunosurveillance and promote tumour development.
Methods

II
One of us, with others,'4 has shown a persistent increase of PGE2 synthesis in the colonic mucosa of rats after treatment with the colonic carcinogen 1,2 Dimethylhydrazine (DMH) -a change which was found in background mucosa and in resulting polyps and cancers. Although the increase in PGE2 could be a secondary response to the carcinogen, the persistence of the increase long after the initial exposure suggests that it is not. Likewise, the presence of increased PG synthesis before detection of cancers suggests that such an increase is not a product of the tumour cell mass. Similarly, N'-methyl-N'-nitro-N-nitroguanidine (MNNG) induced colonic carcinoma has been found to be associated with high levels of PGE2 synthesis at all stages of tumour formation compared with controls, and again significantly increased synthesis was shown before tumour development.6
The suggestion that increased PGE2 synthesis may be important in colonic tumourigenesis has important therapeutic implications. Animal models have shown that certain non-steroidal anti-inflammatory drugs (NSAIDs) can reduce the number of tumours included by various carcinogens.7 91516 Among those actions of NSAIDs which may be anti-carcinogenic is their ability to inhibit PG synthesis. Indomethacin has been shown to enhance lymphocyte function and responses to mitogens in patients with colonic cancer.'4 partly through suppression of monocyte PGE2 synthesis. Indomethacin also has an effect on the cellular immune system that is not dependent on PGs. '7 The association of reduced PG synthesis, NSAIDs, and the suppression of tumourigenesis in animal models has prompted studies into the potentially beneficial effect ofNSAIDs in human colorectal neoplasia. Initial anecdotal reports that sulindac (Clinoral, MSD) caused regression of polyps in patients with familial polyposis and Gardener's syndrome'8 have been confirmed in a controlled trial.'9 The incidence of colorectal cancer is also reduced in regular users of aspirin. 0 II There has been recent interest in the role of diet in colorectal cancinogenesis. There is evidence that the consumption of fish products rich in w-3 fatty acids may protect against colorectal cancer, perhaps through their ability to inhibit cyclo-oxyganase and reduce PG synthesis. 22 Our findings that PGE2 synthesis is increased in premalignant adenomatous polyps and in the background mucosa of those patients with colorectal cancer, suggests that PGE2 may be involved in the progression of the adenomacarcinoma sequence. We postulate that mucosal PGE2 is increased in susceptible individuals in response to an unknown stimulus and that this promotes tumorigenesis. If this is the case, the use of NSAIDs and dietary changes to prevent the recurrence of colonic polyps and colorectal cancer deserves wider study in at risk groups. 
